Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb;19(2):91-8.
doi: 10.1093/pch/19.2.91.

Immunization for meningococcal serogroup B: What does the practitioner need to know?

[Article in English, French]
Joan L Robinson; Canadian Paediatric Society, Infectious Diseases and Immunization Committee

Immunization for meningococcal serogroup B: What does the practitioner need to know?

[Article in English, French]
Joan L Robinson et al. Paediatr Child Health. 2014 Feb.

Abstract
in English, French, French

Most invasive meningococcal disease in Canada is now caused by serogroup B organisms. A vaccine directed against this serogroup (4CMenB) is newly licensed in Canada. A decision will need to be made by all provinces and territories regarding whether a routine infant immunization program is warranted. This decision will need to take into account factors such as uncertain estimates for the effectiveness of the vaccine, the high incidence of fever from the vaccine and the burden of introducing more injections into the current immunization schedule, and consider them against the potentially preventable mortality and morbidity that result from a rare but very serious disease.

Au Canada, la plupart des méningococcies invasives sont désormais causées par des organismes du sérogroupe B. Un vaccin conçu contre ce sérogroupe (4CMenB) vient d’être homologué au Canada. Toutes les provinces et tous les territoires devront décider si un programme de vaccination systématique des nourrissons est justifié. Cette décision devra tenir compte de certains facteurs, tels que les évaluations incertaines de l’efficacité du vaccin, l’incidence élevée de fièvre causée par le vaccin et le fardeau lié à l’introduction d’injections supplémentaires dans le calendrier de vaccination actuel, puis les comparer à la mortalité et à la morbidité potentiellement évitables découlant d’une maladie rare, mais très grave.

Au Canada, la plupart des méningococcies invasives sont désormais causées par des organismes du sérogroupe B. Un vaccin conçu contre ce sérogroupe (4CMenB) vient d’être homologué au Canada. Toutes les provinces et tous les territoires devront décider si un programme de vaccination systématique des nourrissons est justifié. Cette décision devra tenir compte de certains facteurs, tels que les évaluations incertaines de l’efficacité du vaccin, l’incidence élevée de fièvre causée par le vaccin et le fardeau lié à l’introduction d’injections supplémentaires dans le calendrier de vaccination actuel, puis les comparer à la mortalité et à la morbidité potentiellement évitables découlant d’une maladie rare, mais très grave.

Keywords: Meningococcal; Serogroup B; Vaccine.

PubMed Disclaimer

References

    1. Public Health Agency of Canada Invasive meningococcal disease (IMD), Figure 2. 2012. www.phac-aspc.gc.ca/im/vpd-mev/meningococcal-eng.php (Accessed December 16, 2013).
    1. Bettinger JA, Scheifele DW, Le Saux N, et al. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J. 2013;32(1):e20–5. - PubMed
    1. Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: A randomized controlled trial. JAMA. 2012;307(6):573–82. - PubMed
    1. Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: Results of two randomised trials. Lancet. 2013;381(9869):825–35. - PubMed
    1. Prymula R, Vesikari T, Esposito S, et al. Meningococcal B Infant Vaccine Study Group Catch-up vaccination of healthy toddlers with an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) – Exploration of a two-dose schedule. European Society for Paediatric Infectious Diseases Conference; June 7 to 11, 2011; The Hague, The Netherlands.